$119 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 51 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LBIO | New | LION BIOTECHNOLOGIES | $8,104,000 | – | 669,196 | +100.0% | 6.83% | – |
| CEMP | New | CEMPRA | $5,846,000 | – | 170,400 | +100.0% | 4.92% | – |
| ASND | New | ASCENDIS PHARMA A Sspons adr | $3,966,000 | – | 228,612 | +100.0% | 3.34% | – |
| OXFD | New | OXFORD IMMUNOTEC GLOBAL PLC | $3,129,000 | – | 222,226 | +100.0% | 2.64% | – |
| PODD | New | INSULET | $2,077,000 | – | 62,265 | +100.0% | 1.75% | – |
| SPY | New | SPDR S&P 500 ETF TRput | $2,064,000 | – | 10,000 | +100.0% | 1.74% | – |
| AUPH | New | AURINIA PHARMACEUTICALS | $1,875,000 | – | 430,000 | +100.0% | 1.58% | – |
| FLKS | New | FLEX PHARMA | $1,764,000 | – | 90,000 | +100.0% | 1.49% | – |
| AVID | New | AVID TECHNOLOGY | $1,502,000 | – | 100,818 | +100.0% | 1.26% | – |
| New | NEURODERM LTD | $1,385,000 | – | 103,167 | +100.0% | 1.17% | – | |
| EGOV | New | NIC | $1,010,000 | – | 57,143 | +100.0% | 0.85% | – |
| NXTM | New | NXSTAGE MEDICAL | $928,000 | – | 53,665 | +100.0% | 0.78% | – |
| SRNE | New | SORRENTO THERAPEUTICScall | $925,000 | – | 80,000 | +100.0% | 0.78% | – |
| AVEO | New | AVEO PHARMACEUTICALS | $861,000 | – | 593,872 | +100.0% | 0.72% | – |
| EXEL | New | EXELIXIS INCcall | $846,000 | – | 329,000 | +100.0% | 0.71% | – |
| DYAX | New | DYAX CORPcall | $838,000 | – | 50,000 | +100.0% | 0.71% | – |
| AGRX | New | AGILE THERAPEUTICS | $750,000 | – | 80,959 | +100.0% | 0.63% | – |
| OTIC | New | OTONOMY | $707,000 | – | 20,000 | +100.0% | 0.60% | – |
| DSCO | New | DISCOVERY LABORATORIES | $468,000 | – | 393,148 | +100.0% | 0.39% | – |
| SAGE | New | SAGE THERAPEUTICS | $402,000 | – | 8,000 | +100.0% | 0.34% | – |
| SMLR | New | SEMLER SCIENTIFIC | $403,000 | – | 115,148 | +100.0% | 0.34% | – |
| MRNS | New | MARINUS PHARMACEUTICALS | $325,000 | – | 36,107 | +100.0% | 0.27% | – |
| ZSAN | New | ZOSANO PHARMA | $222,000 | – | 21,956 | +100.0% | 0.19% | – |
| ANGO | New | ANGIODYNAMICS | $178,000 | – | 10,000 | +100.0% | 0.15% | – |
| TXMD | New | THERAPEUTICSMD | $114,000 | – | 18,915 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.